FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Can topical coconut oil reduce late-onset sepsis in extremely preterm infants? A pragmatic cluster-randomised controlled trial protocol. PMID 41781050 · BMJ Open · 2026-Mar-04 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Androgen deprivation, androgen receptor-targeted vaccination, and nivolumab in patients with high-risk localized prostate cancer. PMID 41781018 · J Immunother Cancer · 2026-Mar-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Lepodisiran: An Updated Review on a Novel and Emerging Lipoprotein (a) Lowering Agent. PMID 41779052 · Cardiol Rev · 2026-Mar-04 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Clinical effectiveness of transversus abdominis plane block versus local anaesthesia wound infiltration for postoperative pain relief after laparoscopic appendicectomy in children: A multicentre, double-blind, randomised, controlled phase III trial. PMID 41777031 · Eur J Anaesthesiol · 2026-Mar-04 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Once-weekly somapacitan in children with Noonan syndrome: randomized controlled phase 3 trial. PMID 41774755 · Eur J Endocrinol · 2026-Mar-04 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Imipenem/cilastatin/relebactam dosing regimen justification using exposure-efficacy analyses in participants with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia in the RESTORE-IMI 2 phase 3 study. PMID 41586496 · Antimicrob Agents Chemother · 2026-Mar-04 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Sintilimab, pegaspargase, and anlotinib as induction therapy for advanced-stage NKTCL: a multicenter phase II study. PMID 41774854 · Blood Adv · 2026-Mar-03 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A Systematic Review Comparing Sex-Specific Outcomes of Prospective Clinical Trials and Subsequent Real-World Data Focusing on Systemic Treatment Options for Renal Cell Cancer. PMID 41774617 · Urol Int · 2026-Mar-03 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Potential bias in the clinical trial registration of patients with peripheral small-sized non-small cell lung cancer: Real-world data in the era of segmentectomy. PMID 41774196 · Surg Today · 2026-Mar-03 The record describes an observational study analyzing patient selection and registration bias related to the JCOG0802/WJOG4607L trial. It is not a report of a randomized clinical trial with a drug intervention. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effects of exercise and diet in patients with incurable gastroesophageal cancer: the RADICES study. PMID 41592243 · JNCI Cancer Spectr · 2026-Mar-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy. PMID 41493295 · J Am Coll Cardiol · 2026-Mar-03 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial. PMID 41348072 · J Am Coll Cardiol · 2026-Mar-03 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Significant Incidental Findings in the National Lung Screening Trial and Diagnosis of Extrapulmonary Cancer. PMID 41915394 · JAMA Netw Open · 2026-Mar-02 The record is an original analysis from a large randomized trial (NLST). However, it is not eligible because it is a screening/diagnostic study, not a therapeutic trial. It lacks a drug-containing intervention and a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) for a malignant neoplasm. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Radiofrequency Ablation and Chemotherapy vs Chemotherapy Only in Locally Advanced Pancreatic Cancer: The PELICAN Randomized Clinical Trial. PMID 41915391 · JAMA Netw Open · 2026-Mar-02 The record reports a randomized clinical trial in oncology with primary time-to-event endpoints (OS, PFS) and a drug-containing intervention. However, the trial phase (Phase III/IIIb or Phase II/III) is not explicitly stated in the provided metadata, making it impossible to confirm eligibility under the strict criterion requiring explicit phase evidence. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-Term Outcomes of Concurrent Chemoradiotherapy With S-1 in Older Patients With Esophageal Cancer: A Secondary Analysis of a Randomized Clinical Trial. PMID 41893843 · JAMA Netw Open · 2026-Mar-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical Trials. PMID 41885866 · JAMA Netw Open · 2026-Mar-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Bayesian Statistics to Reanalyze Data From the STAAMP Trial. PMID 41842893 · JAMA Netw Open · 2026-Mar-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| VEGF-TKI Outcomes in Metastatic Renal Cell Carcinoma According to Prior Immune Checkpoint Inhibitor or VEGF-TKI: A Scoping Review and Exploratory Analysis. PMID 41827741 · Cancers (Basel) · 2026-Mar-02 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Cost-Effectiveness of Smoking Cessation Among Survivors of Cervical Intraepithelial Neoplasia or Cervical Cancer. PMID 41817524 · JAMA Netw Open · 2026-Mar-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Sivelestat and Incidence of Acute Respiratory Distress Syndrome After Cardiovascular Surgery: A Randomized Clinical Trial. PMID 41811317 · JAMA Netw Open · 2026-Mar-02 The study is a randomized controlled trial of sivelestat vs placebo in cardiovascular surgery patients, reporting on ARDS incidence and 90-day mortality. While it includes a time-to-event outcome (mortality), it is not an oncology study (ARDS is not a human malignant neoplasm). The trial is not identified as Phase III/IIIb or a definitive oncologic trial. Therefore, it does not meet the core eligibility criteria for the oncology Kaplan-Meier digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Bellmunt Risk Score as a Prognostic Tool in Metastatic Castration-Resistant Prostate Cancer Survival. PMID 41790469 · JAMA Netw Open · 2026-Mar-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Key considerations for safe de-escalation of therapy for POLE mutated endometrial cancer. PMID 41775567 · Int J Gynecol Cancer · 2026-Mar-02 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Correction: Psychometric evaluation of a pediatric functional constipation symptom diary using randomized phase 3 clinical trial data. PMID 41770459 · J Patient Rep Outcomes · 2026-Mar-02 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Randomized Trial Links Time of Day to Immunotherapy Success. PMID 41632563 · Cancer Discov · 2026-Mar-02 The record is a news article reporting on a randomized trial, but the abstract lacks explicit details on the trial phase, a specific time-to-event primary/key secondary endpoint, or statistical results like Kaplan-Meier or HR. Therefore, key eligibility criteria cannot be confidently established from the provided metadata. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Effect Modification by Serum Vitamin A Levels on the Association between Vitamin D and Relapse or Death in Patients with Digestive Tract Cancer. PMID 41524587 · Cancer Epidemiol Biomarkers Prev · 2026-Mar-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial. PMID 41504649 · Clin Cancer Res · 2026-Mar-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Deep Learning-Derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-type Metastatic Colorectal Cancer. PMID 41489691 · Clin Cancer Res · 2026-Mar-02 The record is from a randomized oncology trial with drug intervention and time-to-event endpoints. However, the explicit phase (III/IIIb or II/III) is not confirmed in the provided metadata. Per instructions, the phase cannot be inferred. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| ctDNA Detection with Low-Pass Whole-Genome Bisulfite Sequencing in RAS Wild-Type Metastatic Colorectal Cancer: An Exploratory Objective of the VALENTINO Trial. PMID 41427962 · Clin Cancer Res · 2026-Mar-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy. PMID 41405563 · Clin Cancer Res · 2026-Mar-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2- Highly Proliferative Breast Cancer. PMID 41385615 · Clin Cancer Res · 2026-Mar-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| The 3-Year Results of a 100-Patient Prospective Study of the Safety and Effectiveness of Mia Femtech. PMID 41052824 · Aesthet Surg J · 2026-Mar-02 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Efficacy, safety, and immunogenicity of UB-851 versus Eprex® in patients with renal anemia receiving hemodialysis: A randomized, double-masked, phase III trial: Erratum. PMID 41859871 · J Chin Med Assoc · 2026-Mar-01 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study. PMID 41757470 · Cancer Res Commun · 2026-Mar-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Histopathologic growth patterns as prognostic factor for survival in patients with colorectal liver metastases. PMID 41686533 · Radiol Oncol · 2026-Mar-01 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial. PMID 41637102 · JAMA Cardiol · 2026-Mar-01 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Long-Term Safety and Efficacy of Xanomeline and Trospium Chloride in Schizophrenia: A 52-Week Open-Label Extension Trial. PMID 41634905 · Am J Psychiatry · 2026-Mar-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Cancer Incidence and Mortality With Aspirin in Older Adults: Follow-Up of the ASPREE Trial. PMID 41609798 · JAMA Oncol · 2026-Mar-01 This is a secondary analysis of cancer outcomes from the ASPREE trial, which was primarily a cardiovascular prevention trial in older adults. While randomized and drug-interventional (aspirin), it is not a primary report of a Phase III/IIIb or Phase II/III oncology trial, and the reported endpoints are secondary analyses of cancer incidence and mortality, not a primary/key secondary efficacy endpoint for an anticancer drug. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Five-Year Outcome of Camrelizumab Plus Chemotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma: A Secondary Analysis of the CAPTAIN-1st Randomized Clinical Trial. PMID 41609753 · JAMA Oncol · 2026-Mar-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of vunakizumab in patients with moderate-to-severe plaque psoriasis who have a history of systemic therapies: a post hoc analysis of a phase III trial. PMID 41547249 · Int Immunopharmacol · 2026-Mar-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Finerenone in People with CKD, Type 2 Diabetes, and History of Nephrectomy. PMID 41533467 · Clin J Am Soc Nephrol · 2026-Mar-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy of a Phase III Cardiac Rehabilitation Program on Physical Exercise in Patients with Ischemic Heart Disease: A Cluster Randomized Controlled Trial. PMID 41529161 · J Cardiopulm Rehabil Prev · 2026-Mar-01 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Updates in tolerance: future directions to improve kidney allograft survival. PMID 41527400 · Curr Opin Nephrol Hypertens · 2026-Mar-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Dexmedetomidine nasal spray for acute agitation in adults with bipolar disorder: a single-arm open-label trial. PMID 41360383 · J Affect Disord · 2026-Mar-01 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Final Results of the ILLUMINATE-A Phase 3 Clinical Trial of Lumasiran for Primary Hyperoxaluria 1. PMID 41343248 · Clin J Am Soc Nephrol · 2026-Mar-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Age. PMID 41274280 · Inflamm Bowel Dis · 2026-Mar-01 Study is not an oncology trial; it evaluates a drug (ozanimod) for ulcerative colitis (inflammatory bowel disease). While it is a Phase III randomized trial with a drug intervention and original results, it lacks a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) and focuses on safety and clinical/mucosal efficacy rates, not Kaplan-Meier or time-to-event outcomes. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Health-related quality of life with first- vs second-line CDK4/6 inhibitor use in advanced breast cancer: results from the SONIA trial. PMID 41270788 · J Natl Cancer Inst · 2026-Mar-01 The report is a randomized trial in human oncology with a drug intervention, but its primary analysis is focused on health-related quality of life, not a time-to-event efficacy endpoint. The time-to-event outcome (PFS) is mentioned in the background as part of the parent trial's results, but this specific report's methodology and results are dedicated to QoL assessment using patient-reported outcomes, not Kaplan-Meier or HR analysis. Therefore, it does not meet the time-to-event requirement. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety with Upadacitinib by Baseline Corticosteroid Use in Patients with Moderately to Severely Active Crohn's Disease. PMID 41189093 · Inflamm Bowel Dis · 2026-Mar-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Doravirine Resistance Patterns Identified Through Week 192 in the DRIVE-FORWARD and DRIVE-AHEAD Phase 3 Clinical Trials. PMID 41129125 · J Acquir Immune Defic Syndr · 2026-Mar-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The added value of Bayesian interim analysis in randomized phase II and phase III clinical trials in hemato-oncology. PMID 41035401 · Haematologica · 2026-Mar-01 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Toxicities and Quality of Life following Observation or Radiation Therapy for Dupuytren's Disease: Three-Year Secondary Analysis Data From the Prevention Group of the International Dupuytren's Evaluation of Preventative or Adjuvant Radiation Therapy (DEPART) Randomized Trial. PMID 41027544 · Int J Radiat Oncol Biol Phys · 2026-Mar-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |